<DOC>
	<DOCNO>NCT00920088</DOCNO>
	<brief_summary>The purpose study evaluate effect GSK2448761 CYP450 metabolic probe evaluate 2-way interaction GSK2448761 two ritonavir-boosted protease inhibitor commonly use HIV-infected subject .</brief_summary>
	<brief_title>Drug Interaction Study Darunavir/Ritonavir Lopinavir/Ritonavir GSK2248761 PK CYP450 Probe Drugs</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Flurbiprofen</mesh_term>
	<mesh_term>Dextromethorphan</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . Male female 18 50 year age inclusive , time signing informed consent . A female subject eligible participate nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) . Male subject must agree use one contraception method list protocol . This criterion must follow time first dose study medication followup visit . Body weight &gt; =50 kg men &gt; =45 kg woman body mass index ( BMI ) within range 18.531.0 kg/m2 ( inclusive ) . Capable give write informed consent , include compliance requirement restriction list consent form . As result medical interview , physical examination , screen investigation , Investigator considers subject unfit study . The subject positive prestudy drug/alcohol screen . Unwilling refrain use illicit drug adhere protocolstated restriction participate study . History regular alcohol consumption within 6 month study . Unwilling abstain alcohol 48 hour prior start dose collection final pharmacokinetic sample treatment period . History regular use tobacco nicotinecontaining product within 3 month prior screen . History/evidence symptomatic arrhythmia , angina/ischemia , coronary artery bypass grafting ( CABG ) surgery percutaneous transluminal coronary angioplasty ( PCTA ) clinically significant cardiac disease . History/evidence clinically significant pulmonary disease . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . Subjects preexist condition interfere normal gastrointestinal anatomy motility , hepatic and/or renal function , could interfere absorption , metabolism , and/or excretion study drug . Subjects history cholecystectomy exclude . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . The subject receive GSK2248761 previous clinical trial . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Has know intolerance hypersensitivity aspirin , NSAIDS , benzodiazepine , know intolerance active and/or inactive ingredient dextromethorphan , midazolam flurbiprofen ( Cohort 1 ) Has condition symptom contraindicate administration study drug : dextromethorphan , midazolam flurbiprofen . The Investigator reference product information study drug . ( Cohort 1 ) History sensitivity heparin heparininduced thrombocytopenia ( heparin use maintain patency intravenous cannula ) . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen . A positive test HIV antibody . AST , ALT , alkaline phosphatase bilirubin &gt; =1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Pregnant female determine positive serum hCG test screen prior dosing . Lactating female . The subject 's systolic blood pressure outside range 90140mmHg , diastolic blood pressure outside range 4590mmHg heart rate outside range 50100bpm female subject 45100 bpm male subject Screening Day 1 . Cardiac conduction abnormality denote single 12lead ECG screen Day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>probe</keyword>
	<keyword>NNRTI</keyword>
	<keyword>drug interaction</keyword>
	<keyword>protease inhitibor</keyword>
</DOC>